Loading...

MedXY AI/MedXY News/Tag: chronic kidney disease

MedXY News

EnglishTag

chronic kidney disease

58 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Complete Revascularization Benefits Older MI Patients Regardless of Renal Function: Insights from the FIRE Trial

Complete Revascularization Benefits Older MI Patients Regardless of Renal Function: Insights from the FIRE Trial

A sub-analysis of the FIRE trial demonstrates that physiology-guided complete revascularization significantly reduces major adverse cardiovascular events in patients aged 75 and older, irrespective of baseline kidney function, without incre

Section: CardiologyJan 17, 2026

Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF

Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF

A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline

Section: CardiologyJan 17, 2026

Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk

Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk

Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with

Section: CardiologyJan 17, 2026

Protecting Your Kidneys and the Planet: The Impact of the Planetary Health Diet on Chronic Kidney Disease

Protecting Your Kidneys and the Planet: The Impact of the Planetary Health Diet on Chronic Kidney Disease

A large-scale study using UK Biobank data reveals that adhering to a Planetary Health Diet significantly lowers the risk of chronic kidney disease, emphasizing the dual benefits of plant-forward, sustainable eating for both personal health

Section: NephrologyJan 12, 2026

Adherence to the Planetary Health Diet Linked to Significantly Lower Risk of Chronic Kidney Disease, with Stronger Benefits for Women

Adherence to the Planetary Health Diet Linked to Significantly Lower Risk of Chronic Kidney Disease, with Stronger Benefits for Women

A large-scale multi-cohort study involving nearly 190,000 participants reveals that the EAT-Lancet reference diet, measured by the Planetary Health Diet Index, reduces the risk of incident chronic kidney disease, particularly among women, a

Section: NephrologyJan 12, 2026

Saving the Planet, One Kidney at a Time: The Power of the Planetary Health Diet

Saving the Planet, One Kidney at a Time: The Power of the Planetary Health Diet

Recent research from the UK Biobank reveals that a sustainable, plant-forward diet can lower chronic kidney disease risk by 26%, offering a dual solution for environmental and personal health.

Section: NephrologyJan 12, 2026

Finerenone Reduces Albuminuria via Hemodynamic Mechanisms Rather Than Improving Arterial Stiffness: Insights from the FIVE-STAR Trial

Finerenone Reduces Albuminuria via Hemodynamic Mechanisms Rather Than Improving Arterial Stiffness: Insights from the FIVE-STAR Trial

The FIVE-STAR trial demonstrates that while finerenone significantly reduces albuminuria in patients with T2D and CKD, it does not improve arterial stiffness (CAVI). These findings suggest that its cardiorenal benefits are primarily driven

Section: CardiologyJan 11, 2026

Beyond the Arteries: Why Finerenone is a Game-Changer for Diabetic Kidney Disease

Beyond the Arteries: Why Finerenone is a Game-Changer for Diabetic Kidney Disease

The FIVE-STAR trial reveals that finerenone’s cardiorenal benefits stem from reducing internal kidney pressure rather than improving arterial stiffness, offering a new perspective on managing type 2 diabetes and chronic kidney disease.

Section: CardiologyJan 11, 2026

Bone Metabolism Biomarkers: A New Frontier in Predicting Cardiovascular Risk for Diabetes and Renal Disease

Bone Metabolism Biomarkers: A New Frontier in Predicting Cardiovascular Risk for Diabetes and Renal Disease

Recent studies demonstrate that biomarkers of bone metabolism, particularly the OPG/TRAIL ratio, are powerful predictors of cardiovascular disease and mortality in patients with type 2 diabetes and chronic kidney disease, offering improved

Section: CardiologyJan 10, 2026

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial

The DANFLU-2 trial demonstrates that high-dose influenza vaccine provides superior protection against influenza-related hospitalizations in chronic kidney disease and reduces cardiorespiratory hospitalizations in older adults irrespective o

Section: CardiologyDec 26, 2025

Conservative Kidney Management Versus Dialysis in Older Adults with Kidney Failure: Evidence Is Inconclusive — What Clinicians Should Know

Conservative Kidney Management Versus Dialysis in Older Adults with Kidney Failure: Evidence Is Inconclusive — What Clinicians Should Know

A 2025 Cochrane review of 24 non-randomised studies (26,127 participants) found very low‑certainty evidence comparing conservative kidney management (CKM) with dialysis in people aged ≥65 with stage 5 chronic kidney disease; survival and qu

Section: NephrologyDec 16, 2025

Hospital Acute Kidney Injury Strongly Linked to Long-Term Death, Dialysis, and CKD: Meta-Analysis of Matched-Control Studies

Hospital Acute Kidney Injury Strongly Linked to Long-Term Death, Dialysis, and CKD: Meta-Analysis of Matched-Control Studies

A meta-analysis of 14 matched-control studies (n=1,058,109) finds that survivors of in-hospital AKI face higher long-term mortality, greater subsequent dialysis need, and elevated risk of CKD versus matched controls.

Section: Critical CareDec 9, 2025

Empagliflozin Protects the Kidney Across Clinical Spectra — Acute Dip Is Not a Dealbreaker

Empagliflozin Protects the Kidney Across Clinical Spectra — Acute Dip Is Not a Dealbreaker

An individual participant-level meta-analysis of 23,340 participants shows empagliflozin reduces acute and chronic kidney events, slows eGFR decline, and lowers kidney failure risk regardless of predicted acute eGFR dip, diabetes, heart fai

Section: Diabetes & EndocrinologyNov 28, 2025

Balcinrenone plus Dapagliflozin Reduces Albuminuria in CKD: MIRO‑CKD Phase 2b Shows Dose‑Dependent Benefit with Acceptable Safety

Balcinrenone plus Dapagliflozin Reduces Albuminuria in CKD: MIRO‑CKD Phase 2b Shows Dose‑Dependent Benefit with Acceptable Safety

The MIRO‑CKD phase 2b trial found that adding the non‑steroidal MRA balcinrenone to dapagliflozin reduced albuminuria versus dapagliflozin alone in people with CKD, with dose‑dependent effects and modest hyperkalaemia rates over 12 weeks.

Section: Diabetes & EndocrinologyNov 28, 2025

The Vanishing Female Survival Advantage in Stage 5 CKD: Higher Mortality and Lower Receipt of Kidney Replacement Therapy Among Women

The Vanishing Female Survival Advantage in Stage 5 CKD: Higher Mortality and Lower Receipt of Kidney Replacement Therapy Among Women

In a population-based Alberta cohort, women with incident stage 5 CKD lost the usual female survival advantage: younger women had substantially higher excess mortality than men and were less likely to receive transplants or dialysis, indepe

Section: Internal MedicineNov 18, 2025

Clinical Decision Support Tool May Improve ACEI and ARB Use in CKD

Clinical Decision Support Tool May Improve ACEI and ARB Use in CKD

A personalized clinical decision support tool increased 30‑day reinitiation of ACE inhibitors or ARBs from 13% to 18% among veterans with CKD; benefits were modest and limited by population and implementation factors.

Section: Internal MedicineNov 14, 2025

Global CKD Now Affects 788 Million Adults (1990–2023): Rising Prevalence, Growing Mortality, and a Major Cardiovascular Risk

Global CKD Now Affects 788 Million Adults (1990–2023): Rising Prevalence, Growing Mortality, and a Major Cardiovascular Risk

The GBD 2023 analysis estimates 788 million adults living with chronic kidney disease in 2023, rising since 1990, with CKD a top-10 cause of death and a major contributor to cardiovascular mortality. Urgent action on screening, prevention,

Section: NephrologyNov 11, 2025

SGLT2 Inhibitors Reduce Kidney Events, Hospitalization and Death Regardless of Diabetes or Albuminuria: A SMART-C Meta-Analysis Interpretation

SGLT2 Inhibitors Reduce Kidney Events, Hospitalization and Death Regardless of Diabetes or Albuminuria: A SMART-C Meta-Analysis Interpretation

A pooled analysis of 58,816 participants shows SGLT2 inhibitors lower kidney disease progression, AKI, hospitalizations, and mortality across diabetes status and albuminuria levels, with larger absolute kidney benefits where UACR ≥200 mg/g.

Section: Diabetes & EndocrinologyNov 9, 2025

SGLT2 Inhibitors Protect Kidneys Across the Spectrum: Benefits Even in Stage 4 CKD and Minimal Albuminuria

SGLT2 Inhibitors Protect Kidneys Across the Spectrum: Benefits Even in Stage 4 CKD and Minimal Albuminuria

A SMART‑C meta‑analysis of 70,361 participants shows SGLT2 inhibitors reduce CKD progression and kidney failure across eGFR and albuminuria strata, including stage 4 CKD and low albuminuria.

Section: Diabetes & EndocrinologyNov 8, 2025

Dapagliflozin and Cardiac Remodeling in Chronic Kidney Disease: New Evidence for Cardioprotection

Dapagliflozin and Cardiac Remodeling in Chronic Kidney Disease: New Evidence for Cardioprotection

Dapagliflozin reduces left ventricular mass index in chronic kidney disease patients, revealing a key mechanism for cardioprotective effects of SGLT2 inhibitors and highlighting early treatment benefits.

Section: CardiologyOct 31, 2025

Prev 1 2 3 Next